These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26626120)

  • 21. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Corticosteroid withdrawal therapy in patients with chronic hepatitis B virus infection].
    Akuta N; Kumada H
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():345-8. PubMed ID: 15453343
    [No Abstract]   [Full Text] [Related]  

  • 23. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.
    Martin P; Lau DT; Nguyen MH; Janssen HL; Dieterich DT; Peters MG; Jacobson IM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2071-87.e16. PubMed ID: 26188135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
    Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
    J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
    Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
    Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
    Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of novel therapeutics for chronic hepatitis B.
    Xie YH; Hong R; Liu W; Liu J; Zhai JW
    Virol Sin; 2010 Aug; 25(4):294-300. PubMed ID: 20960302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Long-term treatment of chronic hepatitis B and the strategy of anti-virus treatment].
    Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):625. PubMed ID: 15504298
    [No Abstract]   [Full Text] [Related]  

  • 29. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B].
    Ishikawa T; Kakumu S
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():331-5. PubMed ID: 15453340
    [No Abstract]   [Full Text] [Related]  

  • 31. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.
    Zhang TY; Yuan Q; Zhao JH; Zhang YL; Yuan LZ; Lan Y; Lo YC; Sun CP; Wu CR; Zhang JF; Zhang Y; Cao JL; Guo XR; Liu X; Mo XB; Luo WX; Cheng T; Chen YX; Tao MH; Shih JW; Zhao QJ; Zhang J; Chen PJ; Yuan YA; Xia NS
    Gut; 2016 Apr; 65(4):658-71. PubMed ID: 26423112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?
    Koh S; Bertoletti A
    Med Microbiol Immunol; 2015 Feb; 204(1):87-94. PubMed ID: 25511870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection.
    Wei MJ; Pan XN; Wei KP; Li XH; Liu XL; Zhang XM; Jiang YL; Zhang CY; Shen JK
    Int Immunopharmacol; 2015 Aug; 27(2):238-43. PubMed ID: 26118632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of pegylated interferons α-2a and 2b in the treatment of HBeAg-negative chronic hepatitis B infection.
    Karabay O; Tuna N; Esen S;
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1296-301. PubMed ID: 22825647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current issues and future directions in treatment.
    Hui CK; Lau GK
    Semin Liver Dis; 2006 May; 26(2):192-7. PubMed ID: 16673297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H; Jia J
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.